Top Wall Street Stories: Express Scripts Holding Company (NASDAQ:ESRX), Magnum Hunter Resources (NYSE:MHR), Canadian Solar (NASDAQ:CSIQ), ANN INC. (NYSE:ANN), Inovio Pharmaceuticals (NASDAQ:INO)

Express Scripts Holding Company (NASDAQ:ESRX) on Wednesday said the cost of potent, newly approved cholesterol drugs could “wreak financial havoc” among its clients. U.S. regulators last Friday approved the first of the new medicines, Praluent, from Regeneron Pharmaceuticals Inc and Sanofi SA. On 06 August, Express Scripts Holding Company (NASDAQ:ESRX) shares decreased -1.61% and was closed at $89.29. ESRX EPS growth in last 5 year was 11.20%. Express Scripts Holding Company (NASDAQ:ESRX) year to date (YTD) performance is 5.46%.

Magnum Hunter Resources Corp. (NYSE:MHR) will host a conference call on Friday, August 7, 2015, at 9:00 a.m. CDT, to discuss its quarter and six months ended June 30, 2015 financial and operating results. Magnum Hunter Resources Corp. (NYSE:MHR) shares moved up 10.81% in last trading session and ended the day at $0.82. MHR Gross Margin is 80.90% and its return on assets is -20.20%. Magnum Hunter Resources Corp. (NYSE:MHR) quarterly performance is -56.61%.

Canadian Solar Inc. (NASDAQ:CSIQ) announced that it has successfully completed the construction of 100 Megawatt AC (133 Megawatt DC) utility scale Grand Renewable Solar Power plant in Ontario. Canadian Solar Inc. (NASDAQ:CSIQ) ended the last trading day at $25.73. Company weekly volatility is calculated as 6.39% and price to cash ratio as 3.52. Canadian Solar Inc. (NASDAQ:CSIQ) showed a weekly performance of -3.88%.

ANN INC. (NYSE:ANN) is scheduled to report earnings for the current quarter on 28 August 2015. ANN INC. (NYSE:ANN) ended the last trading day at $45.81. Company weekly volatility is calculated as 0.64% and price to cash ratio as 11.95. ANN INC. (NYSE:ANN) showed a weekly performance of 0.50%.

Inovio Pharmaceuticals, Inc. (NASDAQ:INO) announced that its DNA-based monoclonal antibody (dMAb) targeting dengue virus provided protection against a lethal dengue virus challenge in mice. A paper, “Protection against dengue disease by synthetic nucleic acid antibody prophylaxis/immunotherapy,” was published in Scientific Reports, a Nature Publishing Group journal. Inovio Pharmaceuticals, Inc. (NASDAQ:INO) shares fell -5.29% in last trading session and ended the day at $6.80. INO return on assets is -27.30%. Inovio Pharmaceuticals, Inc. (NASDAQ:INO) quarterly performance is -15.84%.

Leave a Reply

Your email address will not be published. Required fields are marked *